Secondary endoscopic submucosal dissection for residual or recurrent tumors after gastric endoscopic submucosal dissection

Shu Hoteya, Toshiro Iizuka, Daisuke Kikuchi, Toshifumi Mitani, Akira Matsui, Osamu Ogawa, Tsukasa Furuhata, Satoshi Yamashta, Akihiro Yamada, Mitsuru Kaise, Naohisa Yahagi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Endoscopic submucosal dissection (ESD) is a widely accepted technique for the management of gastric tumors. However, residual or recurrent tumors can occur after ESD; currently, there is no adequate management strategy for these tumors. Thus, the aim of the present study was to establish a strategy of secondary ESD (sESD) for cases with positive lateral margins (LM+), which cause post-ESD residual or recurrent tumors.

Methods: Fifty-three lesions that were subjected to ESD were diagnosed as LM+ with suspected local residual tumor. The short- and long-term outcomes of early sESD (performed shortly after the initial ESD in LM+ cases to prevent local recurrence) were retrospectively compared with those of late sESD (performed after the detection of recurrent tumors).

Results: Of the 53 LM+ cases, the local residual positive rate was 38.5 % (10/26) in those undergoing early sESD or additional surgery and the local recurrence rate was 29.6 % (8/27) in those that were not treated. Thus, the overall incidence of residual or recurrent tumors in LM+ cases was 34.0 % (18/53). Both early and late sESD had favorable outcomes with no severe complications: 100 % of early sESD resections were curative, compared with 86.7 % of late sESD resections, over the course of a mean (±SD) observation period of 50.8 ± 16.7 months. The performance of early sESD was significantly greater than that of late sESD (in terms of dissection speed).

Conclusions: Early sESD is more reliable than late sESD as a therapeutic strategy for salvaging residual tumors and for preventing recurrence. However, if a tumor has already recurred, late sESD remains useful.

Original languageEnglish
Pages (from-to)697-702
Number of pages6
JournalGastric Cancer
Volume17
Issue number4
DOIs
Publication statusPublished - 2014 Sep 20

Fingerprint

Stomach
Neoplasms
Residual Neoplasm
Recurrence
Endoscopic Mucosal Resection
Dissection
Observation
Incidence

Keywords

  • ESD
  • Gastric tumor
  • Long-term outcomes
  • Residual or recurrent tumors
  • Secondary ESD

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research
  • Medicine(all)

Cite this

Secondary endoscopic submucosal dissection for residual or recurrent tumors after gastric endoscopic submucosal dissection. / Hoteya, Shu; Iizuka, Toshiro; Kikuchi, Daisuke; Mitani, Toshifumi; Matsui, Akira; Ogawa, Osamu; Furuhata, Tsukasa; Yamashta, Satoshi; Yamada, Akihiro; Kaise, Mitsuru; Yahagi, Naohisa.

In: Gastric Cancer, Vol. 17, No. 4, 20.09.2014, p. 697-702.

Research output: Contribution to journalArticle

Hoteya, S, Iizuka, T, Kikuchi, D, Mitani, T, Matsui, A, Ogawa, O, Furuhata, T, Yamashta, S, Yamada, A, Kaise, M & Yahagi, N 2014, 'Secondary endoscopic submucosal dissection for residual or recurrent tumors after gastric endoscopic submucosal dissection', Gastric Cancer, vol. 17, no. 4, pp. 697-702. https://doi.org/10.1007/s10120-013-0325-z
Hoteya, Shu ; Iizuka, Toshiro ; Kikuchi, Daisuke ; Mitani, Toshifumi ; Matsui, Akira ; Ogawa, Osamu ; Furuhata, Tsukasa ; Yamashta, Satoshi ; Yamada, Akihiro ; Kaise, Mitsuru ; Yahagi, Naohisa. / Secondary endoscopic submucosal dissection for residual or recurrent tumors after gastric endoscopic submucosal dissection. In: Gastric Cancer. 2014 ; Vol. 17, No. 4. pp. 697-702.
@article{0058b711f128469cbda37e838468faf9,
title = "Secondary endoscopic submucosal dissection for residual or recurrent tumors after gastric endoscopic submucosal dissection",
abstract = "Background: Endoscopic submucosal dissection (ESD) is a widely accepted technique for the management of gastric tumors. However, residual or recurrent tumors can occur after ESD; currently, there is no adequate management strategy for these tumors. Thus, the aim of the present study was to establish a strategy of secondary ESD (sESD) for cases with positive lateral margins (LM+), which cause post-ESD residual or recurrent tumors.Methods: Fifty-three lesions that were subjected to ESD were diagnosed as LM+ with suspected local residual tumor. The short- and long-term outcomes of early sESD (performed shortly after the initial ESD in LM+ cases to prevent local recurrence) were retrospectively compared with those of late sESD (performed after the detection of recurrent tumors).Results: Of the 53 LM+ cases, the local residual positive rate was 38.5 {\%} (10/26) in those undergoing early sESD or additional surgery and the local recurrence rate was 29.6 {\%} (8/27) in those that were not treated. Thus, the overall incidence of residual or recurrent tumors in LM+ cases was 34.0 {\%} (18/53). Both early and late sESD had favorable outcomes with no severe complications: 100 {\%} of early sESD resections were curative, compared with 86.7 {\%} of late sESD resections, over the course of a mean (±SD) observation period of 50.8 ± 16.7 months. The performance of early sESD was significantly greater than that of late sESD (in terms of dissection speed).Conclusions: Early sESD is more reliable than late sESD as a therapeutic strategy for salvaging residual tumors and for preventing recurrence. However, if a tumor has already recurred, late sESD remains useful.",
keywords = "ESD, Gastric tumor, Long-term outcomes, Residual or recurrent tumors, Secondary ESD",
author = "Shu Hoteya and Toshiro Iizuka and Daisuke Kikuchi and Toshifumi Mitani and Akira Matsui and Osamu Ogawa and Tsukasa Furuhata and Satoshi Yamashta and Akihiro Yamada and Mitsuru Kaise and Naohisa Yahagi",
year = "2014",
month = "9",
day = "20",
doi = "10.1007/s10120-013-0325-z",
language = "English",
volume = "17",
pages = "697--702",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Secondary endoscopic submucosal dissection for residual or recurrent tumors after gastric endoscopic submucosal dissection

AU - Hoteya, Shu

AU - Iizuka, Toshiro

AU - Kikuchi, Daisuke

AU - Mitani, Toshifumi

AU - Matsui, Akira

AU - Ogawa, Osamu

AU - Furuhata, Tsukasa

AU - Yamashta, Satoshi

AU - Yamada, Akihiro

AU - Kaise, Mitsuru

AU - Yahagi, Naohisa

PY - 2014/9/20

Y1 - 2014/9/20

N2 - Background: Endoscopic submucosal dissection (ESD) is a widely accepted technique for the management of gastric tumors. However, residual or recurrent tumors can occur after ESD; currently, there is no adequate management strategy for these tumors. Thus, the aim of the present study was to establish a strategy of secondary ESD (sESD) for cases with positive lateral margins (LM+), which cause post-ESD residual or recurrent tumors.Methods: Fifty-three lesions that were subjected to ESD were diagnosed as LM+ with suspected local residual tumor. The short- and long-term outcomes of early sESD (performed shortly after the initial ESD in LM+ cases to prevent local recurrence) were retrospectively compared with those of late sESD (performed after the detection of recurrent tumors).Results: Of the 53 LM+ cases, the local residual positive rate was 38.5 % (10/26) in those undergoing early sESD or additional surgery and the local recurrence rate was 29.6 % (8/27) in those that were not treated. Thus, the overall incidence of residual or recurrent tumors in LM+ cases was 34.0 % (18/53). Both early and late sESD had favorable outcomes with no severe complications: 100 % of early sESD resections were curative, compared with 86.7 % of late sESD resections, over the course of a mean (±SD) observation period of 50.8 ± 16.7 months. The performance of early sESD was significantly greater than that of late sESD (in terms of dissection speed).Conclusions: Early sESD is more reliable than late sESD as a therapeutic strategy for salvaging residual tumors and for preventing recurrence. However, if a tumor has already recurred, late sESD remains useful.

AB - Background: Endoscopic submucosal dissection (ESD) is a widely accepted technique for the management of gastric tumors. However, residual or recurrent tumors can occur after ESD; currently, there is no adequate management strategy for these tumors. Thus, the aim of the present study was to establish a strategy of secondary ESD (sESD) for cases with positive lateral margins (LM+), which cause post-ESD residual or recurrent tumors.Methods: Fifty-three lesions that were subjected to ESD were diagnosed as LM+ with suspected local residual tumor. The short- and long-term outcomes of early sESD (performed shortly after the initial ESD in LM+ cases to prevent local recurrence) were retrospectively compared with those of late sESD (performed after the detection of recurrent tumors).Results: Of the 53 LM+ cases, the local residual positive rate was 38.5 % (10/26) in those undergoing early sESD or additional surgery and the local recurrence rate was 29.6 % (8/27) in those that were not treated. Thus, the overall incidence of residual or recurrent tumors in LM+ cases was 34.0 % (18/53). Both early and late sESD had favorable outcomes with no severe complications: 100 % of early sESD resections were curative, compared with 86.7 % of late sESD resections, over the course of a mean (±SD) observation period of 50.8 ± 16.7 months. The performance of early sESD was significantly greater than that of late sESD (in terms of dissection speed).Conclusions: Early sESD is more reliable than late sESD as a therapeutic strategy for salvaging residual tumors and for preventing recurrence. However, if a tumor has already recurred, late sESD remains useful.

KW - ESD

KW - Gastric tumor

KW - Long-term outcomes

KW - Residual or recurrent tumors

KW - Secondary ESD

UR - http://www.scopus.com/inward/record.url?scp=84919335670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919335670&partnerID=8YFLogxK

U2 - 10.1007/s10120-013-0325-z

DO - 10.1007/s10120-013-0325-z

M3 - Article

VL - 17

SP - 697

EP - 702

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 4

ER -